Dyne Therapeutics Announces CEO Transition
March 25, 2024 07:30 ET
|
Dyne Therapeutics, Inc.
- John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO - WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc....
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
March 13, 2024 07:30 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
March 05, 2024 07:30 ET
|
Dyne Therapeutics, Inc.
- Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrated Proof-of-Concept, Validating the Promise of the FORCE™ Platform and Targeted Delivery...
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
February 14, 2024 16:15 ET
|
Dyne Therapeutics, Inc.
- Presentations will Highlight Initial Data Announced in January 2024 Demonstrating Proof-of-Concept in its DM1 and DMD Programs, Validating the Promise of the FORCE™ Platform and Targeted Delivery to...
Dyne Therapeutics to Present at February Investor Conferences
February 01, 2024 07:30 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
January 11, 2024 16:05 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 05, 2024 07:30 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock
January 04, 2024 22:46 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
January 03, 2024 16:25 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases
January 03, 2024 06:30 ET
|
Dyne Therapeutics, Inc.
- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose-Dependent Splicing Correction, Muscle Delivery and DMPK Knockdown - - All Evaluable Patients in the 3.4 mg/kg Cohort Treated with DYNE-101...